TQC3927 Inhaled Powder Trial for COPD Shows Preliminary Efficacy and Safety
A multicenter trial is evaluating the efficacy and safety of TQC3927 inhaled powder compared to Glycopyrronium Bromide and Formoterol.
Asset / Drug
Drug and asset intelligence for TQC3927 with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.